What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Orforglipron, Placebo for obesity, overweight, type 2 diabetes.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
There are no specific eligibility criteria for the Master Protocol. * See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes * See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes
Study sites by state
Arizona
- Clinical Research Institute of Arizona (CRI) - Sun City West — Sun City West
- Novak Clinical Research - Tucson - North La Cholla Boulevard — Tucson
California
- Norcal Endocrinology & Internal Medicine — San Ramon
- Southern California Clinical Research — Santa Ana
- Care Access - Thousand Oaks — Thousand Oaks
Florida
- Accel Research Sites - DeLand Clinical Research Unit — DeLand
- Innovation Medical Research Center - Fort Lauderdale — Fort Lauderdale
- Indago Research & Health Center, Inc — Hialeah
- Encore Medical Research — Hollywood
- West Orange Endocrinology P.A. — Ocoee
- Care Access - Tampa — Tampa
- Conquest Research — Winter Park
Georgia
- Accel Research Sites - NeuroStudies Clinical Research Unit — Decatur
- Care Access - Decatur — Decatur
- Javara - Privia Medical Group Georgia - Savannah — Savannah
- North Georgia Clinical Research — Woodstock
Idaho
- Solaris Clinical Research — Meridian
Louisiana
- Care Access - New Iberia — New Iberia
Maryland
- Endocrine and Metabolic Consultants — Rockville
- Javara - Privia Medical Group - Silver Spring — Silver Spring
Michigan
- Great Lakes Research Group, Inc. — Bay City
Montana
- Boeson Research MSO — Missoula
Nevada
- Javara - Nevada Health Centers - Carson City — Carson City
- The Machuca Foundation — Las Vegas
North Carolina
- University of North Carolina Medical Center — Chapel Hill
- Javara - Tryon Medical Partners — Charlotte
- Care Access - Fayetteville — Fayetteville
Oregon
- The Corvallis Clinic, P.C. — Corvallis
Pennsylvania
- Clinical Research of Philadelphia — Philadelphia
- Frontier Clinical Research, LLC — Smithfield
Texas
- Velocity Clinical Research, Dallas — Dallas
- Biopharma Informatic, LLC — Houston
- Activian Clinical Research — Kingwood
- Texas Valley Clinical Research (TVCR) - Mission — Mission
- Consano Clinical Research, LLC — Shavano Park
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)